

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of Entity:</b>	Chimeric Therapeutics Limited (ASX: CHM)
<b>ABN:</b>	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	Dr. Lesley Russell
<b>Date of Appointment:</b>	28 August 2020

### **Part 1 - Director's relevant interests in securities of which the director is the registered holder**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number</b>	<b>Class of Securities</b>
2,750,000	Unlisted Options (subject to escrow for 24 months from official quotation)

---

+ See chapter 19 for defined terms.

## Appendix 3X

### Initial Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>Number</b>	<b>Class of Securities</b>
Nil	Nil	Nil

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Employment Contract
<b>Nature of interest</b>	<p>2,750,000 unlisted options granted from the Company's Omnibus Incentive Plan (OIP).</p> <p>The options will be granted in accordance with the terms of the Company's Omnibus Incentive Plan (OIP) and will include the following terms and conditions:</p> <p>Issue price: Nil.</p> <p>Exercise Price will be at \$0.20 per option.</p> <p>Expiry Date: 18 January 2025</p> <p>Vesting conditions: Vesting annually as follows:</p> <ul style="list-style-type: none"><li>i. 33% will vest upon completion of the offer</li><li>ii. 33% will vest 12 months from completion of the offer.</li><li>iii. The remaining 34% will vest 24 months from completion of the offer.</li></ul>
<b>Name of registered holder (if issued securities)</b>	Dr Lesley Russell
<b>No. and class of securities to which interest relates</b>	2,750,000 unlisted options

---

+ See chapter 19 for defined terms.